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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 28
th
 prioritisation (September 2016), 9 drugs were filtered out of 283 identified and were 
sent to prioritisation. Of these, 7 drugs were ranked as ‘highly relevant’ by the expert panel, 2 as 
‘relevant’ and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No Filtered Drugs – 28
th
 prioritisation 3
rd
 quarter 2016 
Overall 
category 
1. 
Oral ixazomib (MLN9708, Ninlaro
®
), lenalidomide, and dexamethasone for multiple 
myeloma 
Highly 
relevant 
2. Daratumumab (Darzalex
®
), bortezomib, and dexamethasone for multiple myeloma 
Highly 
relevant 
3. 
Nivolumab (Opdivo
®
) in classical Hodgkin lymphoma after autologous stem cell 
transplant and brentuximab vedotin 
Highly 
relevant 
4. 
Fulvestrant plus palbociclib (Ibrance
®
) versus fulvestrant plus placebo for treatment of 
hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on 
previous endocrine therapy 
Highly 
relevant 
5. 
Inotuzumab ozogamicin (CMC-544) versus standard therapy for acute lymphoblastic 
leukemia 
Relevant 
6. 
Olaratumab (Lartruvo
®
) and doxorubicin versus doxorubicin alone for treatment of soft-
tissue sarcoma 
Highly 
relevant 
7. 
Afatinib (Giotrif
®
) versus methotrexate in patients with second-line recurrent and/or 
metastatic head and neck squamous cell carcinoma 
Relevant 
8. 
Pembrolizumab (Keytruda
®
, MK-3475) versus standard treatment for recurrent or 
metastatic head and neck cancer 
Highly 
relevant 
9. 
Nanoliposomal irinotecan (Onyvide
®
) with fluorouracil and folinic acid in metastatic 
pancreatic cancer after previous gemcitabine-based therapy 
Highly 
relevant 
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1 Multiple Myeloma 
1.1 Oral ixazomib (MLN9708, Ninlaro®), lenalidomide, and 
dexamethasone for multiple myeloma 
Overview 
Drug Description 
is a reversible proteasome inhibitor that preferentially binds and inhibits the 
chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome 
Patient Indication 
ixazomib plus lenalidomide–dexamethasone for relapsed, refractory, or relapsed 
and refractory multiple myeloma 
Incidence in Austria 627 newly diagnosed per year (2012), 5.6 /100,000/year 
Ongoing Phase III NCT01564537 - until 05/2019 
Approval 
status for 
this 
indication 
EMA 
On 15 September 2016, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion, recommending the granting of a conditional1 
marketing authorisation for the medicinal product ixazomib, intended for the 
treatment of multiple myeloma. 
FDA 
11/2015: approved for the treatment of patients with multiple 
myeloma who have received at least one prior therapy. 
Approval 
status for 
other 
indications 
EMA 
Ixazomib was designated an ‘orphan medicine’ on 27 September 2011, for the 
treatment of multiple myeloma. 
FDA 
01/2005: approved for the treatment of breast cancer after failure of combination 
chemotherapy for metastatic disease or relapse within 6 months of adjuvant 
chemotherapy. Prior therapy should have included an anthracycline unless 
clinically contraindicated.  
09/2013: approved for metastatic adenocarcinoma of the pancreas as first-line 
treatment, in combination with gemcitabine. 
10/2012: approved for locally advanced or metastatic Non-Small Cell Lung Cancer 
(NSCLC), as first-line treatment in combination with carboplatin, in patients who 
are not candidates for curative surgery or radiation therapy. 
Costs  - 
Phase III results  
NEJM (2016) 374:1621-1634 (Moreau et al.): “Oral Ixazomib, Lenalidomide, and Dexamethasone for 
Multiple Myeloma” 
Background 
Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple 
myeloma. 
 
Methods 
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had 
relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus 
lenalidomide–dexamethasone (ixazomib group) or placebo plus lenalidomide–dexamethasone 
(placebo group). The primary end point was progression-free survival. 
 
Results 
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Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a 
median follow-up of 14.7 months (median progression-free survival, 20.6 months vs. 14.7 months; 
hazard ratio for disease progression or death in the ixazomib group, 0.74; P=0.01); a benefit with 
respect to progression-free survival was observed with the ixazomib regimen, as compared with the 
placebo regimen, in all pre-specified patient subgroups, including in patients with high-risk cytogenetic 
abnormalities. The overall rates of response were 78% in the ixazomib group and 72% in the placebo 
group, and the corresponding rates of complete response plus very good partial response were 48% 
and 39%. The median time to response was 1.1 months in the ixazomib group and 1.9 months in the 
placebo group, and the corresponding median duration of response was 20.5 months and 15.0 
months. At a median follow-up of approximately 23 months, the median overall survival has not been 
reached in either study group, and follow-up is ongoing. The rates of serious adverse events were 
similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were 
the rates of death during the study period (4% and 6%, respectively); adverse events of at least grade 
3 severity occurred in 74% and 69% of the patients, respectively. Thrombocytopenia of grade 3 and 
grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, 
respectively) than in the placebo group (5% and 4% of the patients, respectively). Rash occurred more 
frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did 
gastrointestinal adverse events, which were predominantly low grade. The incidence of peripheral 
neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 
2% of the patients in each study group). Patient-reported quality of life was similar in the two study 
groups. 
 
Conclusions 
The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with 
significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were 
limited. (Funded by Millennium Pharmaceuticals; TOURMALINE-MM1 ClinicalTrials.gov number, 
NCT01564537.) 
1.2 Daratumumab (Darzalex®), bortezomib, and dexamethasone 
for multiple myeloma 
Overview 
Drug Description 
human CD38-directed monoclonal antibody (CD38 is a transmembrane 
glycoprotein (48 kDa) expressed on the surface of hematopoietic cells) 
Patient Indication 
daratumumab in combination with bortezomib and dexamethasone in patients with 
relapsed or relapsed and refractory multiple myeloma. 
Incidence in Austria 627 newly diagnosed per year (2012), 5.6 /100,000/year 
Ongoing Phase III NCT02136134 - until 03/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
05/2016: approved as a monotherapy for the treatment of adult patients with 
relapsed and refractory multiple myeloma, whose prior therapy included a 
proteasome inhibitor and an immunomodulatory agent and who have 
demonstrated disease progression on the last therapy.  
On 17 July 2013, orphan designation was granted by the European Commission to 
Janssen-Cilag International N.V., Belgium, for daratumumab for the treatment of 
plasma-cell myeloma. 
FDA 
11/2015: approved for the administration as a single agent for the treatment of 
patients with multiple myeloma who have received at least three prior lines of 
therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or 
who are double-refractory to a PI and an immunomodulatory agent.  
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Costs  
1 cycle  21 days 
Dexamethasone: in one treatment cycle a dose of 20 mg was administered 8 times 
 total of 160 mg; 100 mg  €28.70 and for 160 mg costs of €45.92 would incur 
for 1 treatment cycle 
Bortezomib: 1.3 mg/square meter body surface administered (subcutaneously) 4 
times per treatment cycle; 3.5 mg  €1,218.95 
assuming a body surface of 1.70 m
2
, 2.21 mg (€769.68) are needed per 
administration and for 1 treatment cycle costs of €3,078.7 would incur 
Daratumumab: 16 mg/kg/once per week (intravenously); 400 mg  €2,209.45; 
assuming an average body weight of 70 kg, 1,120 mg are needed per week and 
3,360 mg are needed for 3 weeks; costs of €18,559.38 would incur for 1 treatment 
cycle  
Total costs of €21,684 for 1 treatment cycle of combination treatment would incur. 
Phase III results  
NEJM (2016) 375:754-766 (Palumbo et al.): “Daratumumab, Bortezomib, and Dexamethasone for 
Multiple Myeloma” 
Background 
Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect 
antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pre-treated 
patients with multiple myeloma, as well as in combination with bortezomib in patients with newly 
diagnosed multiple myeloma. 
 
Methods 
In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory 
multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and 
dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per 
kilogram of body weight) (daratumumab group). The primary end point was progression-free survival. 
 
Results 
A pre-specified interim analysis showed that the rate of progression-free survival was significantly 
higher in the daratumumab group than in the control group; the 12-month rate of progression-free 
survival was 60.7% in the daratumumab group versus 26.9% in the control group. After a median 
follow-up period of 7.4 months, the median progression-free survival was not reached in the 
daratumumab group and was 7.2 months in the control group (hazard ratio for progression or death 
with daratumumab vs. control, 0.39; 95% confidence interval, 0.28 to 0.53; P<0.001). The rate of 
overall response was higher in the daratumumab group than in the control group (82.9% vs. 63.2%, 
P<0.001), as were the rates of very good partial response or better (59.2% vs. 29.1%, P<0.001) and 
complete response or better (19.2% vs. 9.0%, P=0.001). Three of the most common grade 3 or 4 
adverse events reported in the daratumumab group and the control group were thrombocytopenia 
(45.3% and 32.9%, respectively), anaemia (14.4% and 16.0%, respectively), and neutropenia (12.8% 
and 4.2%, respectively). Infusion-related reactions that were associated with daratumumab treatment 
were reported in 45.3% of the patients in the daratumumab group; these reactions were mostly grade 
1 or 2 (grade 3 in 8.6% of the patients), and in 98.2% of these patients, they occurred during the first 
infusion. 
 
Conclusion 
Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in 
combination with bortezomib and dexamethasone resulted in significantly longer progression-free 
survival than bortezomib and dexamethasone alone and was associated with infusion-related 
reactions and higher rates of thrombocytopenia and neutropenia than bortezomib and dexamethasone 
alone. (Funded by Janssen Research and Development; ClinicalTrials.gov number, NCT02136134.)  
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2 Lymphoma 
2.1 Nivolumab (Opdivo®) in classical Hodgkin lymphoma after 
autologous stem cell transplant and brentuximab vedotin 
Overview 
Drug Description humanized IgG4 anti-PD-1 monoclonal antibody 
Patient Indication 
nivolumab for classical Hodgkin lymphoma (cHL) that has relapsed or progressed 
after autologous hematopoietic stem cell transplantation (HSCT) and post-
transplantation brentuximab vedotin 
Incidence in Austria 161 newly diagnosed per year (2012), 1.8/100,000/year 
Ongoing Phase III 
NCT02181738 - until 2018 
NCT01822509 - until 2016 
Approval 
status for 
this 
indication 
EMA - 
FDA 
On May 17, 2016 nivolumab received accelerated approval for the treatment 
of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed 
after autologous hematopoietic stem cell transplantation (HSCT) and post-
transplantation brentuximab vedotin. Based on the results of the CheckMate-205 
and the CheckMate-039 trial. 
Approval 
status for 
other 
indications 
EMA 
05/2016: approved for the treatment of advanced melanoma as a monotherapy or 
in combination with ipilimumab. 
02/2016: approved for the treatment of non-small cell lung cancer (NSCLC) that 
has spread locally or to other parts of the body in patients who have previously 
been treated. 
04/2016: nivolumab as a monotherapy for advanced renal cell carcinoma in 
previously treated patients. 
FDA 
09/2015: approved for BRAF V600 wild-type unresectable or metastatic 
melanoma, as a single agent. 
09/2015: approved for BRAF V600 mutation-positive unresectable or metastatic 
melanoma, as a single agent. 
09/2015: approved for resectable or metastatic melanoma, in combination with 
ipilimumab. 
10/2015: approved for metastatic non-small cell lung cancer and progression on or 
after platinum based chemotherapy. Patients with EGFR or ALK genomic tumour 
aberrations should have disease progression on FDA-approved therapy for these 
aberrations prior to receiving nivolumab. 
11/2015: approved for the treatment of patients with advanced renal cell carcinoma 
who have received prior anti-angiogenic therapy. 
Costs 
 nivolumab conc. 10 mg/ml; 40 ml  €626; nivolumab conc. 10 mg/ml 100 ml: 
€1,517.50. 
The recommended dose-schedule of nivolumab is 3 mg/kg intravenously every 2 
weeks until disease progression or unacceptable toxicity; assuming an average 
body weight of 70 kg, a dose of 210 mg nivolumab would be needed, costing 
€3,186.75 per 2-week cycle and €6,373.5 per month. 
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Phase III results  
Lancet (2016), published online July 20, 2016 (Younes et al.) “Nivolumab for classical Hodgkin’s 
lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a 
multicentre, multicohort, single-arm phase 2 trial” 
Background 
Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterations at the 9p24.1 
locus, leading to overexpression of PD-1 ligands and evasion of immune surveillance. In a phase 1b 
study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed and 
refractory classical Hodgkin's lymphoma, with an acceptable safety profile. We aimed to assess the 
clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin's lymphoma 
after failure of both autologous stem-cell transplantation and brentuximab vedotin. 
 
Methods 
In this ongoing, single-arm phase 2 study, adult patients (aged ≥18 years) with recurrent classical 
Hodgkin's lymphoma who had failed to respond to autologous stem-cell transplantation and had either 
relapsed after or failed to respond to brentuximab vedotin, and with an Eastern Cooperative Oncology 
Group performance status score of 0 or 1, were enrolled from 34 hospitals and academic centres 
across Europe and North America. Patients were given nivolumab intravenously over 60 min at 3 
mg/kg every 2 weeks until progression, death, unacceptable toxicity, or withdrawal from study. The 
primary endpoint was objective response following a pre-specified minimum follow-up period of 6 
months, assessed by an independent radiological review committee (IRRC). All patients who received 
at least one dose of nivolumab were included in the primary and safety analyses. This trial is 
registered with ClinicalTrials.gov, number NCT02181738. 
 
Findings 
Among 80 treated patients recruited between Aug 26, 2014, and Feb 20, 2015, the median number of 
previous therapies was four (IQR 4–7). At a median follow-up of 8·9 months (IQR 7·8–9·9), 53 (66·3%, 
95% CI 54·8–76·4) of 80 patients achieved an IRRC-assessed objective response. The most common 
drug-related adverse events (those that occurred in ≥15% of patients) included fatigue (20 [25%] 
patients), infusion-related reaction (16 [20%]), and rash (13 [16%]). The most common drug-related 
grade 3 or 4 adverse events were neutropenia (four [5%] patients) and increased lipase 
concentrations (four [5%]). The most common serious adverse event (any grade) was pyrexia (three 
[4%] patients). Three patients died during the study; none of these deaths were judged to be treatment 
related. 
 
Interpretation 
Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical 
Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab 
vedotin. Therefore, nivolumab might be a new treatment option for a patient population with a high 
unmet need. Ongoing follow-up will help to assess the durability of response. 
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3 Breast cancer 
3.1 Fulvestrant plus palbociclib (Ibrance®) versus fulvestrant plus 
placebo for treatment of hormone-receptor-positive, HER2-
negative metastatic breast cancer that progressed on previous 
endocrine therapy 
Overview 
Drug Description selective, small molecule inhibitor of cyclin-dependent kinases 4 and 6 
Patient Indication 
palbociclib and fulvestrant in patients with hormone-receptor-positive, HER2-negative 
metastatic breast cancer 
Incidence in Austria 5,594 newly diagnosed per year (2012), 40.3/100,000/year 
Ongoing Phase III NCT01942135 – until January 2017 
Approval 
status for 
this 
indication 
EMA 
On 15 September 2016, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion, recommending the granting of a marketing 
authorisation for the medicinal product palbociclib, intended for the treatment of 
hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) 
negative locally advanced or metastatic breast cancer: 
-in combination with an aromatase inhibitor; 
-in combination with fulvestrant in women who have received prior endocrine therapy. 
FDA 
02/2016: The FDA approved palbociclib for the treatment of hormone receptor (HR)-
positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or 
metastatic breast cancer in combination with fulvestrant in women with disease 
progression following endocrine therapy. 
Approval 
status for 
other 
indications 
EMA - 
FDA 
02/2015: approved for the treatment of hormone receptor (HR)-positive, human 
epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast 
cancer in combination with letrozole as initial endocrine based therapy in 
postmenopausal women. 
Costs - 
Phase III results  
Lancet (2016), published online March 2, 2016 (Cristofanilli & Turner et al.): “Fulvestrant plus 
palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative 
metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of 
the multicentre, double-blind, phase 3 randomised controlled trial” 
Background  
In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant 
was associated with significant improvements in progression-free survival compared with fulvestrant 
plus placebo in patients with metastatic breast cancer. Identification of patients most suitable for the 
addition of palbociclib to endocrine therapy after tumour recurrence is crucial for treatment 
optimisation in metastatic breast cancer. We aimed to confirm our earlier findings with this extended 
follow-up and show our results for subgroup and biomarker analyses. 
 
Methods  
In this multicentre, double-blind, randomised phase 3 study, women aged 18 years or older with 
hormone-receptor-positive, HER2-negative metastatic breast cancer that had progressed on previous 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXVIII – HSS Onkologie Seite 10 von 16 
endocrine therapy were stratified by sensitivity to previous hormonal therapy, menopausal status, and 
presence of visceral metastasis at 144 centres in 17 countries. Eligible patients—ie, any menopausal 
status, Eastern Cooperative Oncology Group performance status 0–1, measurable disease or bone 
disease only, and disease relapse or progression after previous endocrine therapy for advanced 
disease during treatment or within 12 months of completion of adjuvant therapy—were randomly 
assigned (2:1) via a centralised interactive web-based and voice-based randomization system to 
receive oral palbociclib (125 mg daily for 3 weeks followed by a week off over 28-day cycles) plus 
500 mg fulvestrant (intramuscular injection on days 1 and 15 of cycle 1; then on day 1 of subsequent 
28-day cycles) or placebo plus fulvestrant. The primary endpoint was investigator-assessed 
progression-free survival. Analysis was by intention to treat. We also assessed endocrine therapy 
resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA 
mutational status in circulating DNA at baseline. This study is registered with ClinicalTrials.gov, 
NCT01942135. 
 
Results  
Between Oct 7, 2013, and Aug 26, 2014, 521 patients were randomly assigned, 347 to fulvestrant plus 
palbociclib and 174 to fulvestrant plus placebo. Study enrolment is closed and overall survival follow-
up is in progress. By March 16, 2015, 259 progression-free-survival events had occurred (145 in the 
fulvestrant plus palbociclib group and 114 in the fulvestrant plus placebo group); median follow-up was 
8·9 months (IQR 8·7–9·2). Median progression-free survival was 9·5 months (95% CI 9·2–11·0) in the 
fulvestrant plus palbociclib group and 4·6 months (3·5–5·6) in the fulvestrant plus placebo group 
(hazard ratio 0·46, 95% CI 0·36–0·59, p<0·0001). Grade 3 or 4 adverse events occurred in 251 (73%) 
of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant 
plus placebo group. The most common grade 3 or 4 adverse events were neutropenia (223 [65%] in 
the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anaemia 
(ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]). Serious adverse events (all 
causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) 
of 172 patients in the fulvestrant plus placebo group. PIK3CA mutation was detected in the plasma 
DNA of 129 (33%) of 395 patients for whom these data were available. Neither PIK3CA status nor 
hormone-receptor expression level significantly affected treatment response. 
 
Conclusion 
Fulvestrant plus palbociclib was associated with significant and consistent improvement in 
progression-free survival compared with fulvestrant plus placebo, irrespective of the degree of 
endocrine resistance, hormone-receptor expression level, and PIK3CA mutational status. The 
combination could be considered as a therapeutic option for patients with recurrent hormone-receptor-
positive, HER2-negative metastatic breast cancer that has progressed on previous endocrine therapy. 
  
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXVIII – HSS Onkologie Seite 11 von 16 
4 Soft-tissue sarcoma 
4.1 Olaratumab (Lartruvo®) and doxorubicin versus doxorubicin 
alone for treatment of soft-tissue sarcoma 
Overview 
Drug Description 
is a fully human IgG1 monoclonal antibody that targets platelet-derived growth 
factor receptor alpha (PDGFRα) 
Patient Indication 
olaratumab plus doxorubicin in patients with advanced or metastatic soft-tissue 
sarcoma 
Incidence in Austria Austria: 2.4/100,000/year; 11,000 newly diagnosed per year in Europe 
Ongoing Phase III NCT01185964 - until March 2016 
Approval 
status for 
this 
indication 
EMA 
On 15 September 2016, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion, recommending the granting of a conditional1 
marketing authorisation for the medicinal product olaratumab, intended for the 
treatment of advanced soft tissue sarcoma. olaratumab was designated as an 
orphan medicinal product on 12 February 2015.  
FDA - 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
Phase III results  
Lancet (2016), published online: 09 June 2016 (Tap et al.): “Olaratumab and doxorubicin versus 
doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 
2 trial” 
Background 
Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue 
sarcoma and median overall survival for those treated is 12–16 months, but few, if any, novel 
treatments or chemotherapy combinations have been able to improve these poor outcomes. 
Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody that has 
antitumor activity in human sarcoma xenografts. We aimed to assess the efficacy of olaratumab plus 
doxorubicin in patients with advanced or metastatic soft-tissue sarcoma. 
 
Methods 
We did an open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab 
treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the 
USA. For both the phase 1b and phase 2 parts of the study, eligible patients were aged 18 years or 
older and had a histologically confirmed diagnosis of locally advanced or metastatic soft-tissue 
sarcoma not previously treated with an anthracycline, an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0–2, and available tumour tissue to determine PDGFRα expression by 
immunohistochemistry. In the phase 2 part of the study, patients were randomly assigned in a 1:1 ratio 
to receive either olaratumab (15 mg/kg) intravenously on day 1 and day 8 plus doxorubicin (75 mg/m2) 
or doxorubicin alone (75 mg/m2) on day 1 of each 21-day cycle for up to eight cycles. Randomisation 
was dynamic and used the minimisation randomisation technique. The phase 1b primary endpoint was 
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safety and the phase 2 primary endpoint was progression-free survival using a two-sided α level of 0·2 
and statistical power of 0·8. This study was registered with ClinicalTrials.gov, number NCT01185964. 
 
Findings 
15 patients were enrolled and treated with olaratumab plus doxorubicin in the phase 1b study, and 133 
patients were randomised (66 to olaratumab plus doxorubicin; 67 to doxorubicin alone) in the phase 2 
trial, 129 (97%) of whom received at least one dose of study treatment (64 received olaratumab plus 
doxorubicin, 65 received doxorubicin). Median progression-free survival in phase 2 was 6·6 months 
(95% CI 4·1–8·3) with olaratumab plus doxorubicin and 4·1 months (2·8–5·4) with doxorubicin 
(stratified hazard ratio [HR] 0·67; 0·44–1·02, p=0·0615). Median overall survival was 26·5 months 
(20·9–31·7) with olaratumab plus doxorubicin and 14·7 months (9·2–17·1) with doxorubicin (stratified 
HR 0·46, 0·30–0·71, p=0·0003). The objective response rate was 18·2% (9·8–29·6) with olaratumab 
plus doxorubicin and 11·9% (5·3–22·2) with doxorubicin (p=0·3421). Steady state olaratumab serum 
concentrations were reached during cycle 3 with mean maximum and trough concentrations ranging 
from 419 μg/mL (geometric coefficient of variation in percentage [CV%] 26·2) to 487 μg/mL (CV% 
33·0) and from 123 μg/mL (CV% 31·2) to 156 μg/mL (CV% 38·0), respectively. Adverse events that 
were more frequent with olaratumab plus doxorubicin versus doxorubicin alone included neutropenia 
(37 [58%] vs 23 [35%]), mucositis (34 [53%] vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting 
(29 [45%] vs 12 [18%]), and diarrhoea (22 [34%] vs 15 [23%]). Febrile neutropenia of grade 3 or 
higher was similar in both groups (olaratumab plus doxorubicin: eight [13%] of 64 patients vs 
doxorubicin: nine [14%] of 65 patients). 
 
Interpretation 
This study of olaratumab with doxorubicin in patients with advanced soft-tissue sarcoma met its 
predefined primary endpoint for progression-free survival and achieved a highly significant 
improvement of 11·8 months in median overall survival, suggesting a potential shift in the treatment of 
soft-tissue sarcoma. 
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5 Head and neck squamous cell carcinoma 
5.1 Pembrolizumab (Keytruda®, MK-3475) versus standard 
treatment for recurrent or metastatic head and neck cancer  
Overview 
Drug Description a human programmed death receptor-1 (PD-1)-blocking antibody 
Patient Indication 
pembrolizumab for patients with recurrent or metastatic head and neck squamous 
cell carcinoma (HNSCC) 
Incidence in Austria 1,085 newly diagnosed per year (2012), 7.9/100,000/year 
Ongoing Phase III NCT02252042 - until 05/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA 
On August 5, 2016, the U. S. Food and Drug Administration granted accelerated 
approval to pembrolizumab for the treatment of patients with recurrent or 
metastatic head and neck squamous cell carcinoma (HNSCC) with disease 
progression on or after platinum-containing chemotherapy. 
Approval 
status for 
other 
indications 
EMA 
07/2016: approved for the treatment of locally advanced or metastatic non-small 
cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who 
have received at least one prior chemotherapy regimen. Patients with EGFR or 
ALK positive tumour mutations should also have received approved therapy for 
these mutations prior to receiving pembrolizumab. 
07/2015: pembrolizumab as monotherapy is indicated for the treatment of 
advanced (unresectable or metastatic) melanoma in adults. 
FDA 
10/2015: approved for the treatment of patients with advanced (metastatic) non-
small cell lung cancer (NSCLC) whose disease has progressed after other 
treatments and with tumours that express a protein called PD-L1.  
09/2014: approved for the treatment of patients with unresectable or metastatic 
melanoma and disease progression following ipilimumab and, if BRAF V600 
mutation positive, a BRAF inhibitor. 
Costs 
pembrolizumab 50 mg: € 1,812.55 
- patients received 200 mg every 3 weeks (€7,250.2) 
Abstracts 
 2015 ASCO Annual Meeting; Board #407b (Cohen et al.) 
Background 
Prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M 
HNSCC) is poor, with limited treatment options and survival rates of 6-9 months following standard-of-
care (SOC) therapies. Pembrolizumab, a humanized IgG4 monoclonal antibody against PD-1 
designed to block the interaction between PD-1 and its ligands PD-L1 and PD-L2, has demonstrated 
clinical efficacy by investigator review (confirmed and unconfirmed responses) in a phase I study of 
R/M HNSCC. Preliminary PD-L1 biomarker data suggest that response rate may be greater in PD-L1–
positive patients.  
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Methods  
In this global open-label, phase III KEYNOTE-040 (NCT02252042) trial, 466 subjects with recurrent or 
metastatic HNSCC that have failed prior platinum therapy will be randomized (1:1) to pembrolizumab 
(200 mg Q3W) vs investigator’s choice SOC (single-agent methotrexate, docetaxel, or cetuximab). 
Randomization will be stratified by ECOG PS (0 vs 1), human papillomavirus (HPV) status in 
oropharyngeal cancer by p16 immunohistochemistry testing (positive vs negative), and centralized 
PD-L1 status (positive vs negative). Pembrolizumab will be given for ≤ 24 months or until disease 
progression, unacceptable toxicity, or investigator decision. AEs will be assessed according to NCI 
CTCAE, v4.0. Imaging will occur per RECIST v1.1 at 9 weeks and every 6 weeks thereafter. Modified 
RECIST, which allows for continued treatment after initial radiographic progression until confirmation 
imaging ≥ 4 weeks, will be used to account for unique responses seen with pembrolizumab. 
Radiographic responses will be confirmed by independent central review by RECIST v1.1 and 
modified RECIST and analysed in real time for verification of progressive disease by RECIST v1.1. 
Survival follow-up will occur every 12 weeks. Primary end points are progression free survival (PFS) 
and overall survival (OS); secondary end points include ORR, DOR and PFS, OS, and ORR in PD-
L1+ patients. Treatment differences in PFS and OS will be assessed using stratified log-rank test; 
Hazard ratios with 95% confidence intervals will be estimated using stratified Cox proportional hazard 
models. Clinical trial information: NCT02252042 
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6 Pancreatic cancer 
6.1 Nanoliposomal irinotecan (Onyvide®) with fluorouracil and 
folinic acid in metastatic pancreatic cancer after previous 
gemcitabine-based therapy  
Overview 
Drug Description 
is a nanoliposomal formulation of irinotecan hydrochloride (CPT-11), a 
topoisomerase I inhibitor 
Patient Indication 
nanoliposomal irinotecan in combination with fluorouracil and folinic acid, 
compared with a common control (fluorouracil and folinic acid), for patients with 
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine 
based therapy 
Incidence in Austria 1,583 newly diagnosed per year (2012), 9.6 /100,000/year 
Ongoing Phase III - 
Approval 
status for 
this 
indication 
EMA 
On 21 July 2016, the Committee for Medicinal Products for Human Use (CHMP) 
adopted a positive opinion, recommending the granting of a marketing 
authorisation for the medicinal product nanoliposomal irinotecan, intended for the 
treatment of metastatic adenocarcinoma of the pancreas. nanoliposomal irinotecan 
was designated as an orphan medicinal product on 9 December 2011. 
FDA 
10/2015: nanoliposomal irinotecan (irinotecan liposome injection), in combination 
with fluorouracil and leucovorin is approved to treat patients with advanced 
(metastatic) pancreatic cancer who have been previously treated with gemcitabine-
based chemotherapy. 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
Phase III results  
Lancet (2016), published online 22 November 2015 (Wang-Gillam et al.): “Nanoliposomal 
irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-
based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial” 
Background 
Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic 
ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect 
of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this 
population. 
 
Methods 
We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with 
metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were 
randomly assigned (1:1) using an interactive web response system at a central location to receive 
either nanoliposomal irinotecan monotherapy (120 mg/m2 every 3 weeks, equivalent to 100 mg/m2 of 
irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 
mg/m2, equivalent to 70 mg/m2 of irinotecan base) with fluorouracil and folinic acid every 2 weeks was 
added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, 
Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression 
or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat 
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population. The primary analysis was planned after 305 events. Safety was assessed in all patients 
who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506. 
 
Findings 
Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal 
irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or 
fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned 
nanoliposomal irinotecan plus fluorouracil and folinic acid was 6·1 months (95% CI 4·8–8·9) vs 4·2 
months (3·3–5·3) with fluorouracil and folinic acid (hazard ratio 0·67, 95% CI 0·49–0·92; p=0·012). 
Median overall survival did not differ between patients assigned nanoliposomal irinotecan 
monotherapy and those allocated fluorouracil and folinic acid (4·9 months [4·2–5·6] vs 4·2 months 
[3·6–4·9]; 0·99, 0·77–1·28; p=0·94). The grade 3 or 4 adverse events that occurred most frequently in 
the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia 
(32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]). 
 
Interpretation 
Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a 
manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who 
previously received gemcitabine-based therapy. This agent represents a new treatment option for this 
population. 
